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Abstract 
 
Antibiotic resistance is a kind of achievable drug resistance meaning that microorganisms 
are able to sustain and survive exposure to antibiotics. A major contribution to 
development of antibiotic resistance is the abuse of antibiotics in human and in veterinary 
medicine. Antibiotics have been used for many decades but only during recent years 
studies have been published that have increased the understanding in the area of 
antibiotic input and consequences thereof on bacterial resistance. Thus, it was just 
recently published that bacterial strains can undergo rapid selection of resistant mutants at 
antibiotic concentrations far below MIC (Minimal Inhibitory Concentration). However, 
presently there are no studies at low antibiotic concentrations that have been able to show 
whether growth and development of de novo resistant mutants competitively can out 
grow the normal bacterial population. Therefore, the aim of this project was to investigate 
whether de novo resistant mutants of Salmonella typhimurium and Escherichia coli can 
appear and take over the normal bacterial population, and if this occurs also to isolate the 
resistant mutations for characterization. These are closely related bacteria but they differ 
in their target sites for antibiotic resistance i.e. S. typhimurium carries a cryptic 
aminoglycoside resistance gene, aadA, that can be up-regulated and thereby causing 
streptomycin resistance, while  the most common low-cost mutations conferring 
resistance to ciprofloxacin in E. coli are in the gyrase gene gyrA. 
 
The results showed that concentrations of antibiotics far below MIC can select for de 
novo mutants with high antibiotic resistance both in S. typhimurium and E. coli. The 
novel findings regarding these resistant mutants are that they are likely to have lower 
fitness cost than previously studied resistance mutations (such as rpsL mutants for 
streptomycin) which means that these mutations may be new and different from those 
previously described.  
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De novo resistance mutations at sub-MIC levels 
 
Introduction  
 
Antibiotic resistance is a kind of achievable drug resistance meaning that microorganisms 
are able to sustain and survive exposure to antibiotics. A major contribution to 
development of antibiotic resistance is the abuse of antibiotics in human and in veterinary 
medicine (Martinez, 2008). For instance, the misuse and overuse of prescribed antibiotics 
by physicians as well as by patients suffering from non-relevant diseases have resulted in 
a global over consumption of antibiotics. In some countries it is even possible to buy 
antibiotics without any prescription. Antibiotics are also used in veterinary medicine, 
including in animal food for preventing diseases and to increase growth. An estimated 
use of antibiotics in the USA showed that almost 70% of the animal food contains 
antibiotics, and it was suspected that the use of antibiotics in animal food is closely 
related to the development of resistant microorganisms and increased incidence of 
infection-induced diseases (Witte, 1998).  
 
The main reason for development of antibiotic resistance in bacteria, are mutations in 
specific genes. During optimal conditions a bacterial population approximately doubles 
in number every 30 minutes and it can reach a population density of more than 109 
cfu/ml. However, during replication mutations occur frequently, resulting in 105-106, 
gene mutations in each millilitre of the bacterial culture. These mutations often occur as 
silent mutations or are present in non coding regions. However, in some cases the 
mutation leads to lethal alterations in the bacteria or permits selection of new phenotypes 
that make the organism fitter for growth and survival, including for example development 
of antibiotic resistance (Mobashery et al., 2002). 
 
Over the past years, understanding of the mechanisms behind development of antibiotic 
resistance has become an issue of outmost importance for human health and survival. 
Only a few main mechanisms are known to be able to induce bacterial drug resistance. In 
order to prevent uptake of drugs into the cellular environment, the bacteria can alter the 
uptake or efflux system for the drug or could change the composition of their cell 
membrane. If the drug successfully enters the bacteria it may be modified by cellular 
metabolizing enzymes, rendering it inactive. Furthermore, mutations in target sites can on 
the protein/RNA level change the specificity for binding of antibiotics. Which of these 
mechanisms occur depends on the bacterial species, target site, and the type of 
antibiotics. The nature of the antibiotic resistance is also dependent on if mediated by a 
resistance plasmid or by a chromosomal mutation (Mobashery et al., 2002). 
 
Antibiotics have been used for many decades but it is only during recent years that 
studies covering antibiotic input and effects have been published (Kummerer, 2009). 
Thus, it was only recently discovered that bacterial strains can undergo rapid selection of 
pre existing resistant mutants at antibiotic concentrations far below the MIC (Minimal 
Inhibitory Concentration). The definition of MIC is the lowest concentration of an 
antibiotic that is able to inhibit growth of the bacteria. This MIC level differs between 
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different bacterial strains. However, presently there are no studies at low antibiotic 
concentrations that have been able to show whether de novo developed resistant mutants 
competitively can outgrow the normal bacterial population (Gullberg et al., 2011).  
 
Antibiotic resistance is the main driving force of the selection above MIC. However, 
development of mutants having antibiotic resistance often results in decreased bacterial 
fitness, including reduced growth rate and virulence. Since all bacterial competitors will 
die, selection even of mutations associated with a high cost will occur. This is not the 
case at sub-MIC concentrations of antibiotics. At lower concentrations of antibiotics 
competing bacteria will not die but instead decrease their growth rate. As a consequence 
only mutations where the fitness cost is lower than that of competing bacteria will be 
successful for selection and enrichment (Maisnier-Patin et al., 2002).  
 
The aim of the present project was to investigate whether resistant mutations can appear 
de novo and take over the normal bacterial population and, if this occurs, also to isolate 
the resistant mutants for characterization. In this experiment two different strains of 
bacteria were used, Escherichia coli MG1655 and Salmonella typhimurium LT2. They 
are closely related bacteria but differ in their target sites for antibiotic influence. 
S.typhimurium carries a cryptic amino glycoside resistance gene, aadA, that can be up-
regulated and thereby causing streptomycin resistance (Koskiniemi et al., 2011), while  
the most common low-cost mutations conferring resistance to ciprofloxacin in E.coli are 
in the gyrase gene gyrA (Karlsson et al., 2003). 
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Methods and materials 
 
Bacterial strains, stock solutions and growth conditions 
 
Strains 
Strains that were used for this experiment were Escherichia coli MG1655 (DA5438) and 
Salmonella typhimurium LT2 (DA6192). The strains were obtained from the strain 
collection of The Department of Medical Biochemistry and Microbiology (IMBIM).  
 
The MICs for the susceptible strains were for the S. typhimurium wild type 4 µg/ml 
(streptomycin) and for the E. coli wild type 23 ng/ml (ciprofloxacin). 
S. typhimurium was cycled with streptomycin at ¼ and 1/10 of MIC, and E. coli was 
cycled in ciprofloxacin at 1/10 and 1/50 of MIC. The MIC concentrations for 
S. typhimurium and E. coli were provided by my supervisor Dan I. Andersson.  
 
Stock solutions 
Streptomycin stock solution (200mg/ml) 
A stock solution was prepared from 1000 mg streptomycin mixed with 5 ml water. The 
new stock solution was aliquoted and filter sterilized into five 1.5 ml tubes. Thereafter the 
tubes were stored at -20°C.  
 
Streptomycin stock solution (4 mg/ml)  
From the stock solution of streptomycin (200 mg/ml) 200 µl was mixed with 9.8 ml 
water. The new stock solution was aliquoted and filter sterilized into ten 1.5 ml tubes and 
thereafter stored at -20°C until use. 
 
Ciprofloxacin stock solution (9.2 mg/ml) 
A stock solution was prepared from 73.6 mg ciprofloxacin and mixed with 8 ml 0.1M 
NaOH in water. The stock solution was aliquoted and filter sterilized into 1.5 ml tubes 
and thereafter stored at -20°C until use.  
 
Ciprofloxacin stock solution 20x (460 µg/ml) 
From the stock solution of ciprofloxacin (9.2 mg/ml) 500 µl was mixed with 9.5 ml 
water. The new stock solution was aliquoted and filter sterilized into 1.5 ml tubes and 
thereafter stored at -20°C until use.  
 
Ciprofloxacin stock solution 800x (11.5 µg/ml) 
From the stock solution of ciprofloxacin (460 µg/ml) 250 µl was mixed with 10 ml water. 
The new stock solution was aliquoted and filter sterilized into Eppendorf tubes and 
thereafter stored at -20°C. 
 
Liquid growth medium 
The medium used was Mueller-Hinton broth (Becton Dickinson, MD, USA). It was 
prepared by mixing 4.2 gram Mueller-Hinton media with 200 ml water and thereafter 
autoclaved.  
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In the experiments used for growing the bacterial strains Mueller-Hinton medium was 
used that contained different concentrations of streptomycin (1.0 µg/ml and 0.4 µg/ml) 
and ciprofloxacin (2.3 ng/ml and 0.46 ng/ml). The strains were grown at 37°C on a 
shaking board. 
 
 
LB-agar plates 
LB-agar plates were used as a solid medium for screening for resistant the mutants every 
tenth day. For the preparation of plates 20 gram of LB-agar powder (Sigma-Aldrich, MO, 
USA) was mixed with 500 ml water, autoclaved and poured into petri-dishes.  
LB-plates were made that contained different concentrations of streptomycin (8 µg/ml, 
16 µg/ml, 32 µg/ml, 64 µg/ml, 96 µg/ml and 128 µg/ml) and ciprofloxacin (46 ng/ml, 
92 ng/ml, 138 ng/ml and 184 ng/ml).  
 
Growth media containing streptomycin 0.4 µg/ml and 1.0 µg/ml 
From the streptomycin stock solution (4 mg/ml) 10 µl was transferred into an 1.5 ml tube 
containing 0.99 ml Mueller-Hinton medium. The solution was vortexed and 240 µl and 
600 µl was transferred into 50 ml tubes containing 23.76 and 23.40 ml, respectively, to 
reach the final streptomycin concentrations of 0.4 and 1.0 µg/ ml. 
 
Growth media containing ciprofloxacin 0.46 ng/ml and 2.3 ng/ml 
From the ciprofloxacin stock solution (11.5 mg/ml) 10 µl was transferred into an 1.5 ml 
tube containing 0.99 ml Mueller-Hinton medium. The solution was vortexed and 96 µl 
and 480 µl was transferred into 50 ml tubes containing 23.90 ml and 23.52 ml, 
respectively, to reach the final ciprofloxacin concentrations of 0.46 and 2.3 ng/ml. 
 
Cycling the bacteria in growth medium 
The bacterial strains from the -80°C storage were streaked on pre-warmed (37°C) LB-
plates and incubated over night at 37°C. The following day one colony was picked with a 
sterile loop and inoculated into a 10 ml tube containing 1 ml Mueller-Hinton medium. 
The tube was incubated over night on a shaking board at 190 rpm and 37°C. 24 hours 
later the pre culture was diluted by firstly transferring 10 µl from the pre culture to a new 
10 ml tube containing 1 ml Mueller-Hinton. From this tube 1 µl was transferred to a new 
10 ml tube containing 1 ml Mueller-Hinton medium (total dilution 1:10,000) containing 
streptomycin or ciprofloxacin (see the above medium section).  
 
Each day of the experiments 1 µl from the overnight culture was transferred into a new 
10 ml tube containing 1 ml Mueller-Hinton medium with the different concentrations of 
streptomycin or ciprofloxacin. The tubes were incubated on a shaking board at 37°C over 
night.  
 
Every third day during the first 15 days of the experiments, 900 µl of the overnight 
cultures were frozen in -80°C in a freezing tube containing 100 µl dimethyl sulfoxide 
(DMSO). Thereafter, samples were frozen once a week. In order to screen for resistant 
mutants, 1000x dilutions of the overnight cultures were every tenth day spread on pre-
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warmed LB-plates containing different concentrations of streptomycin or ciprofloxacin, 
(see LB-agar plates). To be able to compare the results of development of antibiotic 
resistance also cultures of the wild-type of both bacterial strains were spread out on LB-
plates containing streptomycin or ciprofloxacin.  
 
When mutants with high antibiotic resistance started to appear, colonies were picked and 
restreaked on new plates containing the same antibiotic concentrations to check whether 
persistent resistance had been obtained. Thereafter, these colonies were transferred to 10 
ml tubes containing 1 ml of Mueller-Hinton-medium with the same concentrations of 
antibiotics that were used when cultures were cycled. The tube was placed in the 
incubator over night and thereafter transferred into a freezing tube containing DMSO and 
frozen in -80°C.  
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Results 
 
During the experiments twenty lineages of each strain (E. coli and S. typhimurium), for 
each concentration were used making a total of 100 lineages. Every third day, cultures of 
the lineages were frozen at -80°C, and for every tenth cycle a screening for resistant 
mutants was made on agar plates containing the antibiotics (streptomycin and 
ciprofloxacin). The results from these experiments are shown in Figures 1 and 2.  
 
 
Figure 1. Selection of de novo resistant mutants of S.typhimurium at sub-inhibitory 
concentrations of streptomycin. Twenty independent lineages of S.typhimurium were 
serially passaged in Mueller-Hinton medium containing 1 μg/ml streptomycin. At every 
100 generations a screening for mutants was made on LB-plates containing different 
concentrations of streptomycin and the proportions of resistant mutants were calculated.  
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Figure 2. Selection of de novo resistant mutants of E. coli at sub-inhibitory 
concentrations of ciprofloxacin. Twenty independent lineages of E. coli were serially 
passaged in Mueller-Hinton medium containing 2.3 ng/ml ciprofloxacin. At every 100 
generations a screening for mutants were made on LB-plates containing different 
concentrations of ciprofloxacin and the fractions of resistant mutants were calculated.  
 
 
 
Comparable experiments as reported in Figures 1 and 2 were performed in S. 
typhimurium that was grown in 0.4 µg/ml streptomycin and E. coli that was grown in 
0.46 ng/ml ciprofloxacin. In these experiments, however, no enrichment of resistant 
mutants could be observed.  
 
To be able to compare the results in Figures 1 and 2 with the controls without added 
antibiotics of S. typhimurium and E. coli, overnight culture were accordingly spread out 
on plates containing streptomycin and ciprofloxacin.    
When comparing the background of the controls without added antibiotics with the 
fraction of resistant mutants a clear increase in number of mutants was shown to develop 
for both S. typhimurium (1.0 µg/ml streptomycin) and E. coli (2.3 ng/ml ciprofloxacin). 
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Discussion 
 
The aim of this project was to investigate whether antibiotic resistant mutations with high 
fitness and resistance, could appear de novo and subsequently take over in bacterial 
populations of S. typhimurium and E. coli, and if that occurs to isolate the resistant 
mutants for further characterization. S. typhimurium carries a cryptic aminoglycoside 
resistance gene, aadA, that can be up-regulated and thereby causing streptomycin 
resistance, while  
the most common low-cost mutations conferring resistance to ciprofloxacin in E. coli are 
in the gyrase gene gyrA (Koskiniemi et al., 2011, Karlsson et al., 2003). 
 
S. typhimurium and E. coli that were grown at the higher concentrations of antibiotics 
(streptomycin 1.0 µg/ml and ciprofloxacin 2.3 ng/ml) enriched resistant mutants more 
rapidly than the bacteria that were grown at lower concentrations of the antibiotics 
(streptomycin 0.4 µg/ml and ciprofloxacin 0.46 ng/ml). When comparing S. typhimurium 
and E. coli at higher concentrations of the antibiotics, in the S. typhimurium cultures 
mutants started to enrich gradually from the beginning whereas E. coli did not show any 
enrichment of mutants until after 400 generations. An explanation for this could be that 
streptomycin compared to ciprofloxacin has more potential target sites in the genome for 
development of antibiotic resistance. Another explanation could be that mutants appeared 
but none of them were transferred to the new tube during the cycling procedure since 
only 0.1 % of the cultures were transmitted. 
 
In order to compare the above results that were obtained during the selection of resistant 
mutants (figure 1 and 2 in results) another experiment was performed using the wt of S. 
typhimurium and E. coli. The wt of S.typhimurium and E. coli were similarly spread out 
on LB-plates containing different concentrations of the previously tested antibiotics, 
streptomycin and ciprofloxacin. When the wt background was compared with the fraction 
of resistant mutants a clear increase was shown for both S.typhimurium (1.0 µg/ml 
streptomycin) and E.coli (2.3 ng/ml ciprofloxacin). However, at lower exposures of 
antibiotics S. typhimurium (0.4 µg/ml streptomycin) and E. coli (0.46 ng/ml 
ciprofloxacin) did not show any enrichment of mutants even after 500 generations. A 
possible explanation for this could be that the used concentrations of the antibiotics and 
the time of exposure were not sufficient to show enrichment for mutants. This could 
potentially be answered by using a chemostat experimental setup instead of the 
performed cycling design. Because new medium are continuously added to the culture no 
bottleneck occurs. Mutants that appear will be selected and by time increase in number 
causing the mutated bacterial population to take over. 
 
These results showed that concentrations of antibiotics far below MIC can select for de 
novo mutants with high antibiotic resistance both in S. typhimurium and E. coli. The 
novel findings regarding these resistant mutants are that they are likely to have lower 
fitness cost than previously known resistance mutations (such as rpsL mutants) which 
means that these mutations may be new and different from those previously described 
(Koskiniemi et al., 2011). 
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In conclusion, these experiments show that concentrations of antibiotics far below MIC 
can select for de novo mutants harboring a high antibiotic resistance. Therefore, further 
studies should be performed that will focus on these isolated resistant mutants with the 
aim to identify and characterize the resistance mutations by using transposon mapping 
and whole-genome sequencing. 
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